机构:[1]Centre for Infection and Immunity Studies, School of Medicine, The Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.深圳医学信息中心中国医学科学院阜外医院深圳医院[2]Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong, 999077, China.深圳市康宁医院深圳医学信息中心[3]Department of Rheumatology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.深圳市康宁医院深圳市人民医院深圳医学信息中心[4]Chongqing International Institute for Immunology, Chongqing, 400038, China.[5]Department of Rheumatology and Immunology, Southwest Hospital, The First Hospital Affiliated to Army Medical University, Chongqing, 400038, China.[6]Department of Laboratory Medicine, Affiliated Hospital and Institute of Medical Immunology, Jiangsu University, Zhenjiang, China.[7]Department of Rheumatology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.[8]Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.[9]Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.[10]Department of Rheumatology and Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.[11]Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, Hunan, China.[12]Key Laboratory of Chinese Medicine Rheumatology of Zhejiang Province, Institute of Basic Research in Clinical Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China.[13]Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China.
Chongqing International Institute for
Immunology (2020YJC10), National Natural Science Foundation of China (81901635,
82171782, 82260326, 81971464), Shenzhen Science and Technology Program
(CYJ20210324114602008), Hong Kong Research Grants Council Theme-Based
Research Scheme (T12-703/19 R) and the Centre for Oncology and Immunology
under the Health@InnoHK Initiative by the Innovation and Technology Commission,
Hong Kong, China.
第一作者机构:[1]Centre for Infection and Immunity Studies, School of Medicine, The Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.[2]Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong, 999077, China.[3]Department of Rheumatology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
通讯作者:
通讯机构:[2]Department of Pathology and Shenzhen Institute of Research and Innovation, The University of Hong Kong, Hong Kong, 999077, China.[4]Chongqing International Institute for Immunology, Chongqing, 400038, China.[13]Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China.
推荐引用方式(GB/T 7714):
Ma Kongyang,Du Wenhan,Wang Shiyun,et al.B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation[J].CELLULAR & MOLECULAR IMMUNOLOGY.2023,20(8):881-894.doi:10.1038/s41423-023-01049-2.
APA:
Ma Kongyang,Du Wenhan,Wang Shiyun,Xiao Fan,Li Jingyi...&Lu Liwei.(2023).B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation.CELLULAR & MOLECULAR IMMUNOLOGY,20,(8)
MLA:
Ma Kongyang,et al."B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation".CELLULAR & MOLECULAR IMMUNOLOGY 20..8(2023):881-894